Terms: = Uterine cancer AND TIMP1, CLGI, EPA, EPO, HCI, TIMP, TIMP-1 AND Prognosis
21 results:
1. FTIR Microspectroscopy as a new probe to study human uterine lesions: Characterization of tumor cell lines from uterine smooth muscle cells and evaluation of epa and DHA in vitro treatments.
Belloni A; Notarstefano V; Greco S; Pellegrino P; Giorgini E; Ciarmela P
Biochim Biophys Acta Mol Basis Dis; 2024 Jan; 1870(1):166873. PubMed ID: 37666437
[TBL] [Abstract] [Full Text] [Related]
2. Human Papillomavirus Modulates Matrix Metalloproteinases During Carcinogenesis: Clinical Significance and Role of Viral Oncoproteins.
Mendonça F; Teles AM; Nascimento MDDSB; Santos APAD; Lopes FF; Paiva A; Brito HO; DA Costa RG
In Vivo; 2022; 36(6):2531-2541. PubMed ID: 36309355
[TBL] [Abstract] [Full Text] [Related]
3. Tumoral and stromal expression of MMP-2, MMP-9, MMP-14, timp-1, timp-2, and VEGF-A in cervical cancer patient survival: a competing risk analysis.
Azevedo Martins JM; Rabelo-Santos SH; do Amaral Westin MC; Zeferino LC
BMC Cancer; 2020 Jul; 20(1):660. PubMed ID: 32669083
[TBL] [Abstract] [Full Text] [Related]
4. IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NF-κB signal pathway.
Feng M; Wang Y; Chen K; Bian Z; Jinfang Wu ; Gao Q
PLoS One; 2014; 9(9):e108502. PubMed ID: 25250801
[TBL] [Abstract] [Full Text] [Related]
5. Combination of strong MMP-2 and weak timp-2 immunostainings is a significant prognostic factor in endometrial carcinoma.
Honkavuori-Toivola M; Santala M; Soini Y; Turpeenniemi-Hujanen T; Talvensaari-Mattila A
Dis Markers; 2013; 35(4):261-6. PubMed ID: 24344400
[TBL] [Abstract] [Full Text] [Related]
6. Immunoreactivity for timp-2 is associated with a favorable prognosis in endometrial carcinoma.
Honkavuori-Toivola M; Talvensaari-Mattila A; Soini Y; Turpeenniemi-Hujanen T; Santala M
Tumour Biol; 2012 Aug; 33(4):935-41. PubMed ID: 22270451
[TBL] [Abstract] [Full Text] [Related]
7. Significant relation of tissue inhibitor of matrix metalloproteinase-2 and its combination with matrix metalloproteinase-2 to survival of patients with cancer of uterine cervix.
Wang PH; Ko JL; Yang SF; Tsai HT; Tee YT; Han CP; Lin LY; Chen SC; Shih YT
Reprod Sci; 2011 Aug; 18(8):798-808. PubMed ID: 21422052
[TBL] [Abstract] [Full Text] [Related]
8. High serum timp-1 is associated with adverse prognosis in endometrial carcinoma.
Honkavuori M; Talvensaari-Mattila A; Puistola U; Turpeenniemi-Hujanen T; Santala M
Anticancer Res; 2008; 28(5A):2715-9. PubMed ID: 19035300
[TBL] [Abstract] [Full Text] [Related]
9. [MMP-2/timp-2 expression in the trophoblasts of patients with gestational trophoblastic disease].
Ding F; Zhang QS; Xing FQ
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Feb; 27(2):150-2. PubMed ID: 17355922
[TBL] [Abstract] [Full Text] [Related]
10. Significance of matrix metalloproteinase-7 [correction of matrix metalloproteinase-2], -11 and tissue inhibitor of metalloproteinase-1 expression in normal, hyperplastic and neoplastic endometrium.
Obokata A; Watanabe J; Nishimura Y; Arai T; Kawaguchi M; Kuramoto H
Anticancer Res; 2007; 27(1A):95-105. PubMed ID: 17352221
[TBL] [Abstract] [Full Text] [Related]
11. Promoter methylation of p16, DAPK, CDH1, and timp-3 genes in cervical cancer: correlation with clinicopathologic characteristics.
Jeong DH; Youm MY; Kim YN; Lee KB; Sung MS; Yoon HK; Kim KT
Int J Gynecol Cancer; 2006; 16(3):1234-40. PubMed ID: 16803511
[TBL] [Abstract] [Full Text] [Related]
12. Matrix metalloproteinase-2 (MMP-2) and its tissue inhibitor (timp-2) are prognostic factors in cervical cancer, related to invasive disease but not to high-risk human papillomavirus (HPV) or virus persistence after treatment of CIN.
Branca M; Ciotti M; Giorgi C; Santini D; Di Bonito L; Costa S; Benedetto A; Bonifacio D; Di Bonito P; Paba P; Accardi L; Syrjänen S; Favalli C; Syrjänen K;
Anticancer Res; 2006; 26(2B):1543-56. PubMed ID: 16619570
[TBL] [Abstract] [Full Text] [Related]
13. EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma.
Sier CF; Zuidwijk K; Zijlmans HJ; Hanemaaijer R; Mulder-Stapel AA; Prins FA; Dreef EJ; Kenter GG; Fleuren GJ; Gorter A
Int J Cancer; 2006 Jun; 118(12):2991-8. PubMed ID: 16425263
[TBL] [Abstract] [Full Text] [Related]
14. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract] [Full Text] [Related]
15. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract] [Full Text] [Related]
16. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (timp 2) in stage IB cervical cancer.
Moser PL; Kieback DG; Hefler L; Tempfer C; Neunteufel W; Gitsch G
Anticancer Res; 1999; 19(5C):4391-3. PubMed ID: 10650781
[TBL] [Abstract] [Full Text] [Related]
17. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (timp 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract] [Full Text] [Related]
18. MMP-2 and timp-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization.
Davidson B; Goldberg I; Kopolovic J; Lerner-Geva L; Gotlieb WH; Ben-Baruch G; Reich R
Gynecol Oncol; 1999 Jun; 73(3):372-82. PubMed ID: 10366463
[TBL] [Abstract] [Full Text] [Related]
19. The foundations of successful RT in situ PCR.
Nuovo GJ
Front Biosci; 1996 Nov; 1():c4-15. PubMed ID: 9159200
[TBL] [Abstract] [Full Text] [Related]
20. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma.
Nuovo GJ; MacConnell PB; Simsir A; Valea F; French DL
Cancer Res; 1995 Jan; 55(2):267-75. PubMed ID: 7812956
[TBL] [Abstract] [Full Text] [Related]
[Next]
